Oppenheimer reaffirmed their hold rating on shares of Insys Therapeutics (NASDAQ:INSY) in a report issued on Sunday.

INSY has been the subject of several other research reports. Zacks Investment Research lowered Insys Therapeutics from a hold rating to a sell rating in a research report on Thursday, February 22nd. ValuEngine lowered Insys Therapeutics from a sell rating to a strong sell rating in a research report on Thursday, March 1st. Piper Jaffray Companies lowered Insys Therapeutics from a neutral rating to an underweight rating in a research report on Friday, March 9th. Finally, Cann restated an average rating on shares of Insys Therapeutics in a research report on Friday, March 2nd. Four analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The company has an average rating of Hold and a consensus price target of $9.38.

How to Become a New Pot Stock Millionaire

Insys Therapeutics (INSY) opened at $7.02 on Friday. The company has a market capitalization of $514.68, a PE ratio of -2.23 and a beta of 1.02. Insys Therapeutics has a 12-month low of $4.10 and a 12-month high of $15.02.

Insys Therapeutics (NASDAQ:INSY) last released its quarterly earnings results on Thursday, March 8th. The specialty pharmaceutical company reported ($0.61) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.47). The company had revenue of $31.49 million during the quarter, compared to analysts’ expectations of $34.00 million. Insys Therapeutics had a negative return on equity of 19.79% and a negative net margin of 162.07%. The company’s revenue was down 42.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.03 EPS.

Several large investors have recently made changes to their positions in INSY. Dynamic Technology Lab Private Ltd purchased a new position in shares of Insys Therapeutics during the third quarter valued at approximately $119,000. Janney Montgomery Scott LLC purchased a new position in shares of Insys Therapeutics during the third quarter valued at approximately $135,000. Stone Ridge Asset Management LLC purchased a new position in shares of Insys Therapeutics during the fourth quarter valued at approximately $137,000. Voya Investment Management LLC purchased a new position in shares of Insys Therapeutics during the second quarter valued at approximately $149,000. Finally, Royal Bank of Canada boosted its position in shares of Insys Therapeutics by 100.9% during the second quarter. Royal Bank of Canada now owns 13,695 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 6,877 shares during the period. Institutional investors and hedge funds own 24.19% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Oppenheimer Reiterates Hold Rating for Insys Therapeutics (INSY)” was reported by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://www.dailypolitical.com/2018/03/14/oppenheimer-reiterates-hold-rating-for-insys-therapeutics-insy.html.

About Insys Therapeutics

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Analyst Recommendations for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.